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Cardio–renal interactionMidkine is a multifunctional growth factor, and its serum levels are increased with the functional severity
of heart failure. This study aimed to examine the role of midkine in heart failure pathogenesis. Midkine
expression levels were increased in the kidney and lung after transverse aortic constriction (TAC) surgery,
but not sufﬁciently increased in the heart. After TAC, phosphorylation of extracellular signal-regulated
kinase1/2 and AKT, and the expression levels of foetal genes in the heart were considerably increased
in transgenic mice with cardiac-speciﬁc overexpression of midkine (MK-Tg) compared with wild-type
(WT) mice. MK-Tg mice showed more severe cardiac hypertrophy and dysfunction, and showed lower
survival rate after TAC than WT mice. We conclude that midkine plays a critical role in cardiac hypertro-
phy and remodelling.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction
It is recognized that the presence of cardiovascular disease such
as hypertension, myocardial infarction, and congestive heart fail-
ure increases the risk of kidney dysfunction [1]. In turn, the pres-
ence of chronic kidney disease has been associated with the
deterioration of heart failure [2–4]. Therefore, the underlying
mechanisms of how the heart and kidney interact during cardiac
remodelling need to be determined.
Midkine, a heparin-binding growth factor with a molecular
weight of 13 kDa, has various biological functions, such as for the
growth of ﬁbroblasts [5], survival of embryonic neurons [6], and
migration of inﬂammatory cells [7], elicited through extracellular
signal-regulated kinase (ERK) and AKT activation [6]. As midkine
is strongly expressed in both the early and advanced stages oftumours and organs development [8,9], the involvement of midki-
ne in the progression of carcinogenesis and the pathogenesis of
cardiovascular disease has received attention [10,11].
In experimental models of ischemic heart disease, midkine was
shown to decrease infarction size through its antiapoptotic effect
and vasculogenesis [12,13]. Horiba et al. [14] reported that midki-
ne was associated with vascular stenosis after intraluminal balloon
injury through the recruitment of leucocytes and macrophages.
Similarly, midkine expression is increased in the diabetic or ische-
mic kidney, and it induces tubulointerstitial inﬂammation [11,15].
We have previously reported that serum midkine levels are in-
creased with the functional severity of congestive heart failure, and
are independently associated with adverse cardiac events [16].
However, it remains to be determined whether midkine is associ-
ated with cardiac pathological hypertrophy and remodelling in
pressure overloaded heart. For that purpose, we generated trans-
genic mice with cardiac-speciﬁc overexpression of midkine (MK-
Tg) by using the a-myosin heavy chain (MHC) promoter, and
examined the impact of midkine on cardiac hypertrophy induced
by thoracic transverse aortic constriction (TAC).
2. Methods
2.1. Generation of MK-Tg mice
Human midkine cDNA was generated from A549 cells, and MK-
Tg mice were created at Yamagata University by means of standard
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midkine in the left ventricle by Western blotting (data not shown).
MK-Tg mice and wild-type littermate (WT) mice with a C57/BL6
background were used in the present study. There were no consid-
erable differences in phenotypic features, including general
appearance, body weight, heart weight, wall thickness of the
interventricular septum and posterior wall, left ventricular
end-diastolic dimension (LVEDD), and left ventricular fractional
shortening (LVFS) between the MK-Tg and WT mice at 8–12 weeks
old (data not shown).
All experimental procedures were performed according to the
animal welfare regulations, and the study protocol was approved
by the Animal Subjects Committee of the Yamagata University
School of Medicine. The investigation conformed to the Guide for
the Care and Use of Laboratory Animals published by the US National
Institutes of Health.MK  
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 A2.2. Pressure overload induced cardiac hypertrophy induced by TAC
TAC was performed to induce chronic pressure overload as
described previously [21,22]. Brieﬂy, mice (20–25 g body weight,
8–10 weeks old) were anesthetized by intraperitoneal injection
with a mixture of ketamine (80 mg/kg) and xylazine (8 mg/kg),
and intubated with a 20-gauge polyethylene catheter and venti-
lated with a rodent ventilator (Harvard Apparatus, Holliston,
MA). The chest cavity was opened and the transverse section of
the aorta was freed; an 8-0 prolene suture was passed around
the aorta between the right innominate and left common carotid
arteries; a tight ligature was tied against a 27-gauge needle; and
the needle was then promptly removed.GAPDH  
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 B 2.3. Echocardiography
Transthoracic echocardiography was recorded under anaesthe-
sia with an intraperitoneal injection of pentobarbital sodium
(35 mg/kg), maintaining the heart rate at 450–500 beats/min, as
described previously, using an FF sonic 8900 (Fukuda Denshi Co.,
Tokyo, Japan) [23,24].MK  
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 C 2.4. Histological examination
After mice were euthanized, the heart was ﬁxed with a 10%
solution of formalin, embedded in parafﬁn, and then cut serially
from the apex to the base. The sections were stained with haema-
toxylin-eosin or Masson’s trichrome stain for histopathological
analysis. Transverse sections were captured digitally, and the car-
diomyocyte cross-sectional area was measured using a Scion imag-
ing system (Scion, Frederick, MD) [22,23]. We traced the outline of
at least 200 cardiomyocytes in each section, and the data were
averaged. To assess the degree of ﬁbrosis, the images from at least
10 ﬁelds for each heart were analysed as described previously
[23,25].0  1 3 7 14 28 
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Fig. 1. Changes in midkine expression after TAC surgery. (A) mRNA expression of
midkine in the heart of WT-TAC mice. Protein expression of midkine after TAC was
conﬁrmed in the kidney (B) and the lung (C). Expression levels were expressed as
fold increase over the expression in WT control mice. P < 0.05 vs. control mice.2.5. Western blot analysis
Total proteins were extracted from the left ventricle, lung, and
kidney with ice-cold lysis buffer as described previously [20,22].
Membranes were incubated with the following primary antibod-
ies: anti-phospho-T202/Y204 and anti-total-ERK, anti-phospho-
S473-AKT and total-AKT, b-tubulin (Cell Signaling Technology,
Beverly, MA), and midkine (Sigma, St. Louis, MO). b-Tubulin was
used as a loading control.2.6. RT-PCR and real time RT-PCR
RT-PCR and real time RT-PCR were performed as described
previously [19,26]. The primer sequences for midkine were as
follows: forward 50-GTGACTAAGCCCTGCACCTC-30 and reverse
50-ATCTCTTGTCCCTCCCCACT-30, designed on the basis of Gen-
Bank sequences (NM_001012335.1). Primers for quantitative
real-time RT-PCR were designed on the basis of GenBank se-
quences [atrial natriuretic peptide (ANP), K02781; brain natri-
uretic peptide (BNP), NM 008726; b-MHC, AY056464; a-MHC,
M76601; collagen type I, NM007742; collagen type III,
NM009930; connective tissue growth factor (CTGF), NM010217;
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
NM001001303]. Ampliﬁcation was performed using Light Cycler
DNA Master SYBR Green I in a 20 lL volume reaction and ana-
lysed using Light Cycler Software ver.3.5 (Roche Diagnostics).
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All values are expressed as mean ± the standard error of the
mean (SEM). Differences between groups were evaluated using
one-way analysis of variance with post hoc Bonferroni test. Sur-
vival curves after TAC were generated using the Kaplan–Meier
method and compared using the log-rank test. A P value of <0.05
was considered statistically signiﬁcant. Statistical analysis was
performed with a standard statistical program package (JMP ver-
sion 8; SAS Institute Inc., Cary, NC).3. Results
3.1. MK expression levels in the heart, kidney, and lung after TAC
As we have previously reported that the circulating levels of
midkine increased in heart failure patients, we tried to demon-
strate whether midkine production changed in the process of heart
failure. In the normal condition, midkine was observed to be ex-
pressed in the kidney and lung; however, the expression levels of
midkine were faint in the heart. Sham operation did not change
the midkine expression in the heart, kidney, and lung (data not
shown). After pressure overload was induced, the mRNA expres-
sion levels of midkine in the heart were elevated from 3 days
and peaked at 14 days (Fig. 1a). Interestingly, midkine protein
expression was also increased in the kidney and the lung after
pressure overload (Fig. 1b and c).3.2. Effects of midkine overexpression on the phosphorylation of ERK1/
2 and AKT in the heart after TAC surgery
We suspected that midkine released from kidney and lung
might be involved in the pathogenesis of cardiac remodelling. To0 
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Fig. 2. (A) ERK1/2 and AKT phosphorylation after TAC. Representative Western blot an
expression after TAC. Quantitative analysis of ANF and BNP gene expression and b-M
Expression levels were expressed as fold increase over the expression in WT sham-opertest this hypothesis, we performed TAC surgery in WT and MK-
Tg mice, and the phosphorylation of ERK1/2 and AKT after pressure
overload was investigated. We found that ERK1/2 and AKT were
phosphorylated after TAC; moreover, the phosphorylation level in
MK-Tg mice was higher than in WT mice, as shown in Fig. 2a
(P < 0.05). Although the phosphorylation of p38 MAP kinase and
c-Jun N-terminal kinase increased similarly after TAC, no difference
was observed between the phosphorylation levels in MK-Tg and
WT mice (data not shown).3.3. Expression of foetal genes in hypertrophied hearts
We examined the mRNA expression of foetal genes by using
real time RT-PCR. The expression levels of ANP, BNP, and b-MHC
were considerably increased in the TAC group compared with the
sham surgery group, and these increases were considerably en-
hanced in MK-Tg mice compared with WT mice (Fig. 2b).3.4. Exacerbation of cardiac hypertrophy after TAC in MK-Tg mice
We performed histological examination to evaluate the cardiac
hypertrophy induced by TAC. Fig. 4a shows representative trans-
verse sections of WT and MK-Tg mice hearts after sham or TAC
operation. The heart was considerably larger in MK-Tg mice than
in WT mice at 4 weeks after TAC (Fig. 3a). MK-Tg mice exhibited
considerable increases in heart weight-to-body weight ratio and
left ventricular weight-to-body weight ratio compared with WT
mice after TAC (Table 1). Microscopic analysis also revealed that
the cross-sectional area of cardiomyocytes was considerably in-
creased in MK-Tg mice compared with WT mice after TAC
(Table 1).0 
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Fig. 3. Cardiac hypertrophy and ﬁbrotic changes in MK-Tg mice after TAC. (A) Representative ventricular transverse sections after operation. Bar, 1 mm. (B) Representative
histological micrographs of haematoxylin-eosin staining after operations. Bar, 20 lm. (C) Quantitative analysis of collagen type I and type III, and connective tissue growth
factor mRNA gene expression (n = 8). Each expression level was normalized to the GAPDH level and expressed as fold increase over the level in the WT sham-operated mice.
P < 0.01 vs. WT sham-operated mice.
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To examine whether pressure overload could induce distinct
pathological differences between MK-Tg and WT mice after TAC,
Masson trichrome staining was performed on heart sections to
evaluate cardiac ﬁbrosis. As shown in Fig. 3b, pressure overload in-
duced more severe cardiac ﬁbrosis in MK-Tg mice than in WT mice
after TAC. We next examined the expression of collagen type I, col-
lagen type III, and CTGF. The expression levels of these molecules
after TAC were higher in MK-Tg mice than in WT mice (Fig. 3c).3.6. Impaired cardiac function after pressure overload in MK-Tg mice
We observed that cardiac hypertrophy and ﬁbrosis were en-
hanced in MK-Tg mice, and we suspected that cardiac function
was attenuated in MK-Tg mice compared with WT mice. Represen-
tative M-mode echocardiograms at 4 weeks after operation are
shown in Fig. 4a. As we expected, MK-Tg mice showed a greater
LVEDD with decreasing LVFS compared with WT mice after TAC(Table 1). The persistent pressure overload induced congestive
heart failure, which was manifested by a lower survival rate up
to 4 weeks after TAC in MK-Tg mice than in WT mice (50% vs.
76%, P < 0.05), as shown in Fig. 4b. These results suggested that
MK-Tg mice showed cardiac hypertrophy and dysfunction after
pressure overload.4. Discussion
In the present study, we demonstrated the critical role of in-
creased expression of midkine in the development of cardiac
hypertrophy and heart failure. After induction of pressure over-
load, midkine expression was increased mainly in the lung and
the kidney. Phosphorylation of ERK1/2 and AKT in the heart after
pressure overload was considerably increased in MK-Tg mice com-
pared with WT mice. At 4 weeks after TAC, MK-Tg mice showed
more severe left ventricular hypertrophy and ﬁbrotic change than
WT mice. The expression levels of cardiac foetal genes were con-
siderably increased in MK-Tg mice compared with WT mice after
Table 1
Gravimetric data and cardiac function (echocardiographic and cardiac catheter) after TAC or sham operation.
WT-sham Tg-sham WT-TAC Tg-TAC
BW (g) 26.5 ± 0.7 25.8 ± 0.8 25.0 ± 0.5 24.8 ± 0.6
HW/BW (mg/g) 4.46 ± 0.12 4.89 ± 0.27 6.47 ± 0.45* 8.24 ± 0.56**,#
LVW/BW (mg/g) 3.05 ± 0.12 3.64 ± 0.21 4.98 ± 0.20** 7.36 ± 0.23**,##
Cross sectional area (lm2) 194 ± 9 234 ± 32 307 ± 33** 359 ± 23**,##
Echocardiographic data
IVS (mm) 0.79 ± 0.04 0.79 ± 0.03 1.09 ± 0.06** 0.98 ± 0.03**
PW (mm) 0.93 ± 0.03 0.87 ± 0.05 1.10 ± 0.07 0.97 ± 0.10
LVEDD (mm) 2.73 ± 0.08 2.87 ± 0.04 3.36 ± 0.11** 4.06 ± 0.14**,##
LVFS (%) 43.2 ± 0.7 40.5 ± 1.1 35.1 ± 2.5* 20.3 ± 2.0**,##
HR (bpm) 449 ± 24 421 ± 15 428 ± 10 431 ± 47
Data are presented as mean ± SEM (n = 8–10). TAC, transverse aortic constriction; LVW, left ventricular weight; left ventricular weight; IVS, interventricular septum; PW,
posterior wall; LVEDD, left ventricular end-diastolic dimension; LVFS, left ventricular fractional shortening; HR, heart rate, respectively.
* P < 0.05 vs. sham-operated WT mice.
** P < 0.01 vs. sham-operated WT mice.
# P < 0.05 vs. WT-TAC mice.
## P < 0.01 vs. WT-TAC mice.
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mice than in WT mice. These data suggest that overexpression of
midkine deteriorates the cardiac hypertrophic response induced
by pressure overload and results in the development of heart
failure.
Nevertheless, even with existing pharmacological therapies, the
incidence of heart failure is still increasing [27]. Current medical
treatments for the prevention of cardiac hypertrophy rely on phar-
macologic blockade of receptors that respond to neuroendocrine
stimuli [28]. Therefore, it is believed that direct and indirect inter-
actions between the heart and the kidney can initiate the patho-
physiological linkage [2,4,29]. We have previously shown that
the circulating level of midkine is independently associated with
the severity and onset of cardiac events in patients with heart
failure [16]. However, the mechanisms by which serum levels ofmidkine increase in heart failure patients are unknown. Midkine
is most intensely expressed during midgestation, whereas the
expression is weak or absent in most normal adult tissues except
the kidney. Reynolds et al. [30] reported that hypoxia induces mid-
kine expression through the binding of hypoxia inducible factor-1a
in adult mice. Moreover, Hobo et al. [31] reported that 5/6
nephrectomy induces midkine expression in the kidney and lung.
In the present study, after TAC operation, protein levels of midkine
were increased in the kidney and the lung, but were not substan-
tially increased in the heart. The maximum increase in midkine
expression occurred at 14–28 days after TAC (Fig. 1). Therefore,
midkine expression in the kidney and the lung induced by TAC
may be associated with organ hypoxia accompanying cardiac
hypertrophy and cardiac dysfunction. Considering these results,
midkine secreted from the kidney and lung may be associated with
cardio–renal interaction.
Although midkine levels were increased in the kidney and lung,
the role of midkine on the pathogenesis of heart failure after pres-
sure overload has not been evaluated. In the present study, car-
diac-speciﬁc overexpression of midkine exacerbates cardiac
dysfunction and pathological remodelling in mice with pressure
overload-induced heart failure. Previous studies showed that mid-
kine had a cardioprotective effect in experimental ischemic heart
models. Midkine-deﬁcient mice showed larger infarct size than
did WT mice after ischemia/reperfusion and myocardial infarction
[12,13,32]. Midkine has various biological effects, including cell
survival, migration, and neurite outgrowth [33]. These cardiopro-
tective effects of midkine might be elicited by the activation of
antiapoptotic signals and promotion of angiogenesis [12,13]. Previ-
ously, the antiapoptotic effect and angiogenesis induced by midki-
ne were reported to be associated with the activation of ERK and
phosphatidylinositol 3-kinase (PI3K)/AKT. However, it is also rec-
ognized that the ERK and PI3K/AKT pathways are involved in car-
diac hypertrophy induced by mechanical stress [34,35]. ERK1/2
becomes activated in cardiomyocytes in response to G protein-
coupled receptor agonists, receptor tyrosine kinase agonists, cyto-
kines, and stretch, and is involved in cardiac hypertrophy [36].
Moreover, several growth factors bind to their membrane-bound
tyrosine kinase receptors and activate a 110-kDa lipid kinase
PI3K/AKT pathway [34], which was associated with not only phys-
iological hypertrophy but also maladaptive hypertrophy [34,35].
Therefore, it is suspected that increased levels of midkine en-
hanced the activation of the ERK1/2 and AKT pathways after pres-
sure overload, and induced cardiac hypertrophy and heart failure.
This hypothesis was supported by the fact that phosphorylation
of ERK1/2 and AKT considerably increased in the hearts of MK-Tg
210 S. Netsu et al. / Biochemical and Biophysical Research Communications 443 (2014) 205–210mice compared withWTmice after TAC (Fig. 2). Increasing levels of
midkine have cardioprotective effects on experimental models of
ischemic heart disease through antiapoptotic effect and angiogen-
esis; however, these also have adverse effects on cardiac hypertro-
phy induced by chronic pressure overload. These results suggest a
crucial role of midkine as a novel therapeutic target for heart
failure.
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